Avui, dilluns 8 de juny, el Dipòsit Digital no estarà operatiu de 15:00 a 17:00 h per tasques de manteniment. Disculpeu les molèsties.
Hoy, lunes 8 de junio, el Dipòsit Digital no estará operativo de 15:00 a 17:00 h debido a tareas de mantenimiento. Disculpen las molestias.
Today, Monday, Jun 8th, the Digital Repository will be unavailable due to a system update.

Document type

Article

Version

Accepted version

Publication date

Publication license

cc-by-nc-nd (c) Cortex - Publicacoes Tecnicas e Cientificas, 2019
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/164999

Cost-effectiveness of insulin degludec versus insulin glargine U100 in patients with type 1 and type 2 diabetes in Portugal: evidence from SWITCH 1&2 trials

Journal Title

Director/Tutor

Journal ISSN

Volume Title

Related resource

Abstract

Objectives: To assess the cost-effectiveness of insulin degludec (degludec) versus insulin glargine (glargine) U100 from a Portuguese healthcare perspective using data from SWITCH 1 & 2 trials. - - - Methods: A short-term model estimated cost-effectiveness of degludec versus glargine U100 in type 1 diabetes (T1DM) basal bolus (B/B) and type 2 diabetes (T2DM) basal oral therapy (BOT) patients. The model captured hypoglycaemia rates and insulin dosing. Clinical outcomes were obtained from SWITCH 1 & 2. Disutilities related to hypoglycaemic events and insulin, needles and blood glucose tests costs were also included. Benefits were measured in QALYs. One-way and probabilistic sensitivity analyses were conducted (...)

Citation

Citation

DARBÀ, Josep, et al. Cost-effectiveness of insulin degludec versus insulin glargine U100 in patients with type 1 and type 2 diabetes in Portugal: evidence from SWITCH 1&2 trials. Revista Portuguesa de Diabetes. 2019. Vol. 14, num. 4, pags. 141-150. ISSN 1646-3439. [consulted: 8 of June of 2026]. Available at: https://hdl.handle.net/2445/164999

Export metadata

JSON - METS

Share record